Literature DB >> 31028214

Early Second Round Targeted Biopsy of PI-RADS Score 3 or 4 in 256 Men With Persistent Suspicion of Prostate Cancer.

Pietro Pepe1, Antonio Garufi2, Gian Domenico Priolo2, Michele Pennisi3, Filippo Fraggetta4.   

Abstract

BACKGROUND/AIM: The aim of the study was to determine the rate of clinically significant prostate cancer (csPCa) cases in men submitted to early second round mpMRI/TRUS (multiparametric magnetic resonance imaging/transrectal ultrasound) fusion biopsy (TPBx).
MATERIALS AND METHODS: From January 2016 to December 2018, 256 men with a PI-RADS (Prostate Imaging-Reporting and Data System) score 3 (80 cases) or 4 (176 cases) and negative repeat transperineal saturation biopsy plus TPBx, underwent a new TPBx (four cores) for the persistent clinical suspicion of cancer. The accuracy of mpMRI ADC (apparent diffusion coefficient) values in the diagnosis of csPCa were evaluated.
RESULTS: Overall detection rate of csPCa was equal to 10.1% (26/256 cases): 2.5% (2/80) versus 13.6% (24/176) had a PI-RADS score equal to 3 versus 4, respectively. The presence of csPCa was significantly correlated with an ADC value of 0.747×10-3 mm2/sec.
CONCLUSION: A negative TBPx missed a csPCa in 13.6% of PI-RADS score 4 that was diagnosed by an early second round TBPx; the evaluation of ADC maps could select mpMRI lesions deserving a repeat TPBx. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  MRI and prostate cancer; Prostate cancer; repeat MRI/TRUS targeted prostate biopsy; transperineal targeted biopsy

Mesh:

Substances:

Year:  2019        PMID: 31028214      PMCID: PMC6559925          DOI: 10.21873/invivo.11556

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  1 in total

1.  Axumin (18F-Fluciclovine) PET imaging in men exhibiting no clinically significant cancer on initial negative biopsy of PI-RADS 4 and 5 regions of interest.

Authors:  Ezequiel Becher; Shawn Karls; Angela Tong; James S Wysock; Samir S Taneja; William C Huang; Herbert Lepor
Journal:  World J Urol       Date:  2022-10-05       Impact factor: 3.661

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.